KALA BIO, Inc.
KALA
$0.58
$0.024.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.66M | 1.74M | 9.86M | 4.53M | 4.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.72M | 1.80M | 10.23M | 10.66M | 10.88M |
| Operating Income | -1.72M | -1.80M | -10.23M | -10.66M | -10.88M |
| Income Before Tax | -1.58M | -1.62M | 686.00K | -7.56M | -11.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.58M | -1.62M | 686.00K | -7.56M | -11.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.58M | -1.62M | 686.00K | -7.56M | -11.16M |
| EBIT | -1.72M | -1.80M | -10.23M | -10.66M | -10.88M |
| EBITDA | -1.64M | -1.72M | -10.17M | -10.53M | -10.81M |
| EPS Basic | -21.32 | -0.14 | 2.70 | -53.70 | -85.64 |
| Normalized Basic EPS | -13.32 | -0.09 | -19.61 | -48.75 | -52.79 |
| EPS Diluted | -21.32 | -0.14 | 2.70 | -53.70 | -85.64 |
| Normalized Diluted EPS | -13.32 | -0.09 | -19.61 | -48.75 | -52.79 |
| Average Basic Shares Outstanding | 74.20K | 11.87M | 253.70K | 140.80K | 130.30K |
| Average Diluted Shares Outstanding | 74.20K | 11.87M | 253.70K | 140.80K | 130.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |